This symposium will feature background on tirzepatide, the study design and objectives, results, and implications for the present and future of care. The session will begin at 8:00 a.m. CT on Saturday in Great Hall B at the convention center. A livestream and on-demand recording are available at ADA2022.org.
Starting soon: SURMOUNT-1—Results of The First Phase 3 Obesity Trial with The Novel GIP/GLP-1 Receptor Agonist Tirzepatide
